GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--GE HealthCare announces additional clinical applications now available as part of the OEC 3D mobile CBCT C-arm portfolio.

GE HealthCare Announces Advanced Imaging Innovations for OEC 3D C-arm to Help Improve Precision Care in Practice of Interventional Pulmonology

GE HealthCare hosted an analyst event on Thursday. Solid guidance fell on deaf ears.

GE HealthCare Guidance Was Good. The Stock Dropped Anyway.

Expands accessibility for institutions utilizing GE HealthCare MRI systems Expands accessibility for institutions utilizing GE HealthCare MRI systems

FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems

GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.

GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strate.

GE HealthCare hosts 2024 Investor Day: focus on innovation to deliver precision care and drive growth

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed Journal of Clinical Anesthesia, highlighting performance of the wireless and wearable Portrait™ Mobile monitoring solution in the post-surgical ward environment. With published alarm rates from critical care and cardiac telemetry units that number in the hundreds per bed per day, healthcare systems may be concerned with.

Pilot Study Showcases the Value of Portrait Mobile Continuous Monitoring Solution to Encourage Clinical Intervention While Mitigating Alarm Fatigue

GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.

GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging

GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.

GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The FDA clearance of SIGNA MAGNUS underscores the advances made by GE HealthCare in neuroimaging. It features an innov.

GE HealthCare Receives FDA Clearance for Head-Only SIGNA MAGNUS 3.0T MRI System

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an initiative with AMN Healthcare aimed at helping address the critical shortage of radiologic technologists (rad tech) in the healthcare industry. This initiative helps healthcare providers meet their immediate staffing needs through AMN Healthcare's comprehensive workforce solutions and GE HealthCare's innovative technologies and training expertise. Several factors contributing to the current shortage of rad techs include.

GE HealthCare Announces Initiative to Help Address Radiologic Technologist Shortage

RadNet

Radnet Inc   (NASDAQ:RDNT) stock is soaring, last seen up 24% to trade at $89.11 at last glance, after the company reported better-than-expected earnings and revenue for the third quarter.

RadNet Stock Pops on Earnings, GE HealthCare Partnership

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced a strategic collaboration to further the innovation, commercialization, and adoption of AI in imaging. Together, the two companies aim to develop SmartTechnology™ solutions that harness the transformative power of AI to address key challenges across the imaging value chain, including helping i.

GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closin.

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Ae.

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required. The live webcast will be available at https://investor.gehealthcare.com/news-events/events.The press release, presentation, and w.

GE HealthCare to Host its 2024 Investor Day on November 21

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock

GE Healthcare Technologies gets a buy rating, agreeing with today's Wall Street and SA analyst consensus. The firm's recent Q3 results showed growth indicators in multiple segments, despite headwinds from China, and will be crucial in supplying in-demand contrast dyes used in medical imaging. The stock is still undervalued on multiple fronts (EV/EBITDA, P/E), despite the share price trending above its moving average.

GE HealthCare: Light Up With Growth Indicators In Medical Tech, While Undervalued

GE HealthCare's spin-off has unlocked valuation potential, allowing each former GE segment to thrive independently and attract market-specific growth. The company's Q3 showed steady revenue and margin gains, driven by operational efficiencies and growth in high-demand medical technologies. With advancements in AI and diagnostics, GE HealthCare is well-positioned to capture market share, though growth faces temporary headwinds in China.

From Spin-Off To Standout: GE HealthCare Is Pretty Impressive

GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.

GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up

GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Carolynne Borders - Chief Investor Relations Officer Peter Arduini - President and Chief Executive Officer Jay Saccaro - Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - J.P. Morgan Ryan Zimmerman - BTIG Joanne Wuensch - Citi David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Sezgi Ozener - HSBC Navann Ty - BNP Paribas Operator Thank you for standing by, and welcome to GE HealthCare's Third Quarter 2024 Earnings Conference Call.

GE HealthCare Technologies Inc. (GEHC) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GE HealthCare (GEHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

GE HealthCare (GEHC) reported better profits than expected for the third quarter as its sales were roughly in line with estimates.

GE HealthCare's Profit Beats Estimates While China Sales Struggle

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.99 per share a year ago.

GE HealthCare Technologies (GEHC) Tops Q3 Earnings Estimates

GE HealthCare Technologies beat estimates for quarterly profit on Wednesday as strong demand for its medical devices in the U.S. offset slowing sales in China due to disruptions in the country's healthcare sector because of an anti-corruption drive.

GE HealthCare beats Q3 profit estimates on U.S. demand for medical devices

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024. GE HealthCare President and CEO Peter Arduini said, “In the third quarter, we reported sales and orders growth of 1% globally. Both sales and orders grew in the mid-single digits excluding China, with particular strength in the U.S. across all segments. Pharmaceutical Diagnostics also delivered solid performance, driven by healthy procedure volumes. Ongoing lea.

News for GE HealthCare Technologies Inc Stock (GEHC)